Research Topics
| DAVID HASTINGS contact CRIBBSSummaryAffiliation: University of California Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray studyDavid H Cribbs
Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, 1226 Gillespie NRF, Irvine, CA 92697, USA
J Neuroinflammation 9:179. 2012..This study undertakes a systematic and comprehensive analysis of brain gene expression profiles of immune/inflammation-related genes in aging and Alzheimer's disease (AD)...- Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) miceIrina Petrushina
The Institute for Brain Aging and Dementia, University of California Irvine, Irvine, CA 92697 4540, USA
J Neuroinflammation 5:42. 2008..In the current study, we tested the efficacy of this vaccine configuration in amyloid precursor protein (APP) transgenic mice (Tg2576)... - Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloidKathryn E Nichol
Institute for Brain Aging and Dementia, University of California, Irvine, Irvine, CA, USA
J Neuroinflammation 5:13. 2008..Our objective was to determine if exercise could induce a shift from the immune profile in aged (17-19 months) Tg2576 mice to a response that reduces Abeta pathology... - Abeta DNA vaccination for Alzheimer's disease: focus on disease preventionDavid H Cribbs
Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, 92697 4540, USA
CNS Neurol Disord Drug Targets 9:207-16. 2010.... - Caspase-mediated degeneration in Alzheimer's diseaseDavid H Cribbs
Institute for Brain Aging and Dementia, Irvine CA 92697-4540, USA
Am J Pathol 165:353-5. 2004 - Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic miceIrina Petrushina
The Institute for Brain Aging and Dementia, University of California, Irvine, Irvine, California 92697 4540, USA
J Neurosci 27:12721-31. 2007.... - Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloidDavid H Cribbs
Institute for Brain Aging and Dementia, University of California Irvine, Irvine, CA 92697-4540, USA
Int Immunol 15:505-14. 2003.... 
Fas and Fas ligand are associated with neuritic degeneration in the AD brain and participate in beta-amyloid-induced neuronal deathJoseph H Su
Institute for Brain Aging and Dementia, 1113 Gillespie Neuroscience Research Facility, University of California Irvine, 92697 4540, USA
Neurobiol Dis 12:182-93. 2003..These findings suggest that Fas-FasL interactions may contribute to mechanisms of neuronal loss and neuritic degeneration in AD...
Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathologySalvatore Oddo
Department of Neurobiology and Behavior, University of California, Irvine, Irvine, California 92697, USA
J Neurosci 28:12163-75. 2008..These data highlight the critical role CHIP plays as a link between Abeta and tau and identify CHIP as a new potential target not only for AD but for other neurodegenerative disorders characterized by tau accumulation...- Immunization with amyloid-beta attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse modelMasashi Kitazawa
Department of Neurobiology and Behavior and Neurology, University of California, Irvine, California 92697 4545, USA
J Neurosci 29:6132-41. 2009..These findings provide support for the hypothesis that Abeta is one of the key pathogenic components in IBM pathology and subsequent skeletal muscle degeneration... - Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasomeSalvatore Oddo
Institute for Brain Aging and Dementia, University of California, Irvine, Irvine, CA 92697, USA
Neuron 43:321-32. 2004..These findings indicate that Abeta immunization may be useful for clearing both hallmark lesions of AD, provided that intervention occurs early in the disease course... - Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylationAnna Parachikova
Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697 4545, USA
J Alzheimers Dis 21:527-42. 2010.... - Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tanglesSalvatore Oddo
Departments of Neurobiology and Behavior and Neurology, and Institute for Brain Aging and Dementia, University of California, Irvine, California 92697, USA
J Biol Chem 281:39413-23. 2006..Notably, reducing soluble Abeta alone did not improve the cognitive phenotype in mice with plaques and NFTs. Our results show that Abeta immunotherapy reduces soluble tau and ameliorates behavioral deficit in old transgenic mice... - A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brainFloyd Sarsoza
Institute for Brain Aging and Dementia, University of California, Irvine, CA 92697, USA
Acta Neuropathol 118:505-17. 2009.... - Linear and conformation specific antibodies in aged beagles after prolonged vaccination with aggregated AbetaVitaly Vasilevko
The Institute for Memory Impairments and Neurological Disorders, University of California, Irvine 92697 4540, USA
Neurobiol Dis 39:301-10. 2010..Our findings indicate that prolonged immunization results in distinctive temporal changes in antibody profiles, which may be important for other experimental and clinical settings... - Beta-amyloid deposition and neurofibrillary tangle association with caspase activation in Down syndromeElizabeth Head
Institute for Brain Aging and Dementia, University of California at Irvine, Irvine, CA 92697 4540, USA
Neurosci Lett 330:99-103. 2002..Abeta within or around neurons in addition to contributing to NFT formation may also trigger apoptotic pathways. Caspase activation may lead to the cleavage of critical cellular proteins and neuronal cell death associated with DS... - Immunization with fibrillar Abeta(1-42) in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain AbetaElizabeth Head
Institute for Brain Aging and Dementia, Department of Neurology, University of California, 1259 Gillespie Neuroscience Research Facility, Irvine, CA 92697 4540, USA
Vaccine 24:2824-34. 2006..A nonsignificant increase in CSF Abeta(1-40) and decrease in Abeta(1-40/1-42) in cortex was detected. Canines may be a useful system for testing an Abeta vaccine... - Relapsing polychondritis with features of dementia with Lewy bodiesElizabeth Head
Institute for Brain Aging and Dementia, University of California, Irvine, CA 92697 4540, USA
Acta Neuropathol 112:217-25. 2006..This study demonstrates that qualitatively similar inflammation-associated neurodegeneration is present in widespread regions of the brain in a RP case presenting clinically as DLB... - Experimental investigation of antibody-mediated clearance mechanisms of amyloid-beta in CNS of Tg-SwDI transgenic miceVitaly Vasilevko
The Institute for Brain Aging and Dementia, University of California, Irvine, Irvine, California 92697 4540, USA
J Neurosci 27:13376-83. 2007..Thus, approaches that deliver immunotherapy to the brain may be more effective at clearing Abeta than immunization strategies in which the majority of the antibodies are in the periphery... - Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapyVitaly Vasilevko
Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA
Ann N Y Acad Sci 1207:58-70. 2010..Thus, there is a critical need for new strategies that improve BBB function and limit the development of β-amyloidosis in the cerebral vasculature... - The induction of the TNFalpha death domain signaling pathway in Alzheimer's disease brainMing Zhao
Institute for Brain Aging and Dementia, University of California Irvine, Irvine, California, USA
Neurochem Res 28:307-18. 2003..Our findings suggest that the TNF death receptor pathway and caspases are activated in the early stages of neuronal degeneration in AD... - Importance of IgG2c isotype in the immune response to beta-amyloid in amyloid precursor protein/transgenic miceIrina Petrushina
The Institute for Brain Aging and Dementia, University of California Irvine, Irvine, CA 92697-4540, Irvine USA
Neurosci Lett 338:5-8. 2003..Our results suggest that APP/Tg2576 and major histocompatibilty complex-matched parental strains are not expressing IgG2a, producing instead IgG2c anti-Abeta antibodies... - Mimotopes of conformational epitopes in fibrillar beta-amyloidGoar Gevorkian
, ,
J Neuroimmunol 156:10-20. 2004.... - Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptideMichael G Agadjanyan
Institute for Molecular Medicine, Department of Immunology, Huntington Beach, CA 92647, USA
J Immunol 174:1580-6. 2005..New preclinical trials in amyloid precursor protein transgenic mouse models may help to develop novel immunogen-adjuvant configurations with the potential to avoid the adverse events that occurred in the first clinical trial... - Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switchAnahit Ghochikyan
Department of Immunology, Institute for Molecular Medicine, Huntington Beach, CA 92647-3652, USA
Vaccine 24:2275-82. 2006..These results suggest that switching from Alum to Quil A would be beneficial for AD patients because anti-Abeta antibody production was enhanced without changing the initially generated and likely beneficial Th2-type humoral response... - Abeta-immunotherapy for Alzheimer's disease using mannan-amyloid-Beta peptide immunoconjugatesAnahit Ghochikyan
The Institute for Molecular Medicine, Department of Immunology, Huntington Beach, California, USA
DNA Cell Biol 25:571-80. 2006..New preclinical trials in AD mouse models may help to develop novel immunogen-adjuvant configurations with the potential to avoid the adverse immune response that occurred in the first clinical trial... - Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategyNina Movsesyan
Department of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, California, United States of America
PLoS ONE 3:e2124. 2008.... - Amyloid-beta peptide binds to microtubule-associated protein 1B (MAP1B)Goar Gevorkian
Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico, Apartado Postal 70228, Cuidad Universitaria, Mexico DF, CP 04510, Mexico
Neurochem Int 52:1030-6. 2008..This interaction may explain, in part, the loss of neuronal cytoskeletal integrity, impairment of microtubule-dependent transport and synaptic dysfunction observed previously in Alzheimer's disease... - Novel approaches for immunotherapeutic intervention in Alzheimer's diseaseVitaly Vasilevko
The Institute for Brain Aging and Dementia, University of California Irvine, Irvine, CA 92697-4540, United States
Neurochem Int 49:113-26. 2006.... - Phagocytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer's diseaseMilan Fiala
Department of Medicine, UCLA VA School of Medicine, Los Angeles, CA, USA
J Alzheimers Dis 11:457-63. 2007..Finally, peripheral blood leukocytes are a superior model system for investigation of innate immune dysfunction in Alzheimer's disease... - Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvantDmitri Loukinov
National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
J Cell Biochem 98:1037-43. 2006..This is the first report demonstrating the feasibility of vaccination with a cancer associated epigenetic regulator for the induction of tumor inhibition... - Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigeneAnahit Ghochikyan
The Institute for Molecular Medicine, Department of Immunology, Huntington Beach, USA
Eur J Immunol 33:3232-41. 2003..The DNA minigene-induced anti-Abeta antibodies bound to Abeta plaques in brain tissue from an Alzheimer's disease patient demonstrating functional activity of the antibodies and the potential for therapeutic efficacy... - Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomersGrigor Mamikonyan
Department of Immunology, The Institute for Molecular Medicine, Huntington Beach, California 92647, USA
J Biol Chem 282:22376-86. 2007.... - Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sitesAnahit Ghochikyan
Department of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA 92647, USA
J Immunol 178:566-73. 2007..These cytolytic responses were observed across a wide range of different mouse cancers including mammary adenocarcinoma, glioma, leukemia, and mastocytoma...
Research Grants
- Combining AD epitope vaccine with innate immunityDAVID HASTINGS contact CRIBBS; Fiscal Year: 2010..In current project we propose to generate safe and effective epitope vaccine that may prevent/reduce development of Alzheimer's disease pathology in pre-symptomatic people diagnosed with early-stage AD. ..
- Combining AD epitope vaccine with innate immunityDavid Cribbs; Fiscal Year: 2009..In current project we propose to generate safe and effective epitope vaccine that may prevent/reduce development of Alzheimer's disease pathology in pre-symptomatic people diagnosed with early-stage AD. ..
- Multiple Approaches to Abeta Vaccination in Animal ModelsDavid Cribbs; Fiscal Year: 2009..Additional studies will focus on identifying risk factors associated with immunizing elderly patients and developing protective therapies to eliminate these risk factors. ..
- Multiple Approaches to Abeta Vaccination in Animal ModelsDavid Cribbs; Fiscal Year: 2007..Additional studies will focus on identifying risk factors associated with immunizing elderly patients and developing protective therapies to eliminate these risk factors. ..
- Combining AD epitope vaccine with innate immunityDavid Cribbs; Fiscal Year: 2007..We believe that this approach will provide a more comprehensive assessment of the overall efficacy of immunotherapy as a potential clinical approach for treating AD. ..
- Multiple Approaches to ABeta Vaccination in Animal Mode*David Cribbs; Fiscal Year: 2005..Therefore, both prophylactic and therapeutic vaccination will be tested. ..
- Multiple Approaches to Abeta Vaccination in Animal ModelsDAVID HASTINGS CRIBBS; Fiscal Year: 2010..Additional studies will focus on identifying risk factors associated with immunizing elderly patients and developing protective therapies to eliminate these risk factors. ..